What does this research mean for the field?

Adding testosterone replacement therapy (TRT) to tirzepatide in late responders improves weight loss quality, prevents muscle depletion, and restores sexual and metabolic health in obese hypogonadal men. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the effect of testosterone undecanoate therapy combined with tirzepatide in obese hypogonadal men who are late responders.

March 12, 2026Open Access

Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study

Key Points

To evaluate the effect of testosterone undecanoate therapy combined with tirzepatide in obese hypogonadal men who are late responders.
Pilot study design focusing on late responders to tirzepatide.
Participants included obese hypogonadal men.
Testosterone undecanoate was administered as an add-on therapy alongside tirzepatide.
Evaluations included assessment of weight, muscle health, and metabolic parameters.
The dual therapy improved weight loss quality compared to tirzepatide alone.
Participants showed less muscle depletion with combined treatment.
Restoration of metabolic and sexual health was observed in participants.

Abstract

Our preliminary findings suggest that adding TRT to tirzepatide in late tirzepatide responders who are hypogonadal may optimize weight loss quality, prevent muscle depletion, and restore sexual and metabolic health. This dual pharmacological approach represents a promising precision medicine strategy for managing complex phenotypes of male obesity-associated hypogonadism.

Read Full Paperexternally

Perguntar à IA

Bookmark

View Full Paper